Dendritic Cell Vaccine (DCVax-L): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

11 November 2024

31 March 2024

  • curprev 13:0113:01, 31 March 2024‎ Lazy talk contribs‎ 6,839 bytes +6,839‎ Created page with "{{TreatmentInfo |drug_name=Dendritic Cell Vaccine (DCVax-L) |FDA_approval=Under investigation; not yet FDA-approved |used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent |clinical_trial_phase=Phase 3 |common_side_effects=Intracranial edema, nausea, lymph node infection (rare and manageable) |OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence |OS_with=Median overall survival of 19.3 months..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Dendritic_Cell_Vaccine_(DCVax-L)"